US SB4426 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on May 23 2024 - 25% progression, died in committee
Action: 2024-05-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 23 2024 - 25% progression, died in committee
Action: 2024-05-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
Title
Promising Pathway Act 2.0
Sponsors
| Sen. Mike Braun [R-IN] | Sen. Kirsten Gillibrand [D-NY] | Sen. Kevin Cramer [R-ND] | Sen. Joe Manchin [D-WV] |
| Sen. Eric Schmitt [R-MO] | Sen. Alex Padilla [D-CA] | Sen. J.D. Vance [R-OH] | Sen. Cory Booker [D-NJ] |
| Sen. Josh Hawley [R-MO] | Sen. Peter Welch [D-VT] | Sen. Lisa Murkowski [R-AK] | Sen. Richard Durbin [D-IL] |
History
| Date | Chamber | Action |
|---|---|---|
| 2024-05-23 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/senate-bill/4426/all-info |
| Text | https://www.congress.gov/118/bills/s4426/BILLS-118s4426is.pdf |
